Alcon reported a resilient Q4 2024 with revenue of $2.502 billion and a gross profit of $1.385 billion, marking a gross margin of 55.36%. Operating income reached $395 million with an operating margin of 15.78%, while net income stood at $284 million and diluted EPS at $0.57. The quarter generated strong operating cash flow of $462.9 million and free cash flow of $313.2 million, supporting a cash balance of approximately $1.676 billion and a net debt position of about $3.45 billion. The company maintained solid liquidity (current ratio 2.77) and a healthy balance sheet, supported by a substantial asset base (total assets ~$30.35 billion) and modest leverage (total debt to capitalization ~19.2%). Despite a year-over-year net income decline (YoY margin pressure contributing to a -33.5% net income YoY change), the QoQ trajectory was positive with net income up ~8%, and EPS up ~7.6% QoQ, underscoring resilience in a steadier demand environment for ophthalmic devices.
Looking ahead, Alcon’s cash-generative profile and diversified product portfolio across Surgical and Vision Care position the company to fund R&D, pursue selective acquisitions, and sustain shareholder-friendly capital allocation. While explicit forward guidance for 2025 is not provided in the dataset, the balance sheet strength and cash conversion cycle dynamics imply potential for continued margin stability and modest revenue progression, contingent on macro FX conditions and end-market demand for cataract/refractive procedures and eye-care consumables.